EP2462946A1 - Procédé d'inhibition de l'activité de la cathepsine - Google Patents
Procédé d'inhibition de l'activité de la cathepsine Download PDFInfo
- Publication number
- EP2462946A1 EP2462946A1 EP12157648A EP12157648A EP2462946A1 EP 2462946 A1 EP2462946 A1 EP 2462946A1 EP 12157648 A EP12157648 A EP 12157648A EP 12157648 A EP12157648 A EP 12157648A EP 2462946 A1 EP2462946 A1 EP 2462946A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- igfbp
- seq
- amino acids
- cathepsin
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1754—Insulin-like growth factor binding proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to methods for inhibiting angiogenesis, tumorigenesis and cathepsin activity, particularly in mammalian cells.
- IGFBP insulin-like growth factor binding protein
- IGFBP1 insulin-like growth factor binding protein
- IGFBP1 insulin-like growth factors
- Cathepsins are proteases, normally present in lysosomes, which play an important role in many physiological processes such as protein degradation, antigen presentation, and bone resorption. In tumors and activated cells, cathepsins can be translocated to the membrane and secreted to extracellular spaces, participating in degradation of extracellular matrix (ECM), facilitating in this manner cell migration.
- ECM extracellular matrix
- lysosomal cysteine protease cathepsin B has been recently implicated in tumor dissemination and angiogenesis.
- the proteolytic activity of cathepsin B facilitates direct degradation of various ECM proteins, including laminin, fibronectin, tenascin C, and type IV collagen, the latter being a major component of ECM and the vascular basement membrane.
- IGFBP-4 IGFBP-4
- CIBP-4 C-terminal protein fragment of IGFBP-4
- TY thyroglobulin type I
- IGFBPs insulin-like growth factor binding proteins
- IGFBP-1 IGFBP-1
- IBP2 IGFBP-2
- IBP-3 IBP3
- IGFBP-4 IGFBP4
- IGFBP-5 IBP5
- IGFBP-6 IGFBP-6
- IGFBP-1 IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6 or a variant of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6, for inhibiting angiogenesis.
- IGFBP-1 IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6 or a variant of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6, for inhibiting tumorigenesis.
- IGFBPs Insulin-like growth factor binding proteins
- IGFBPs include, for example, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 or a mixture thereof.
- Variants of such proteins are preferably the C-terminal protein fragments of the IGFBPs, particularly the thyroglobulin type I (TY) domain in the C-terminal fragments.
- variants preferably have an amino acid sequence having at least 70% sequence identity to one of the IGFBPs, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity.
- variants preferably have an amino acid sequence having at least 70% sequence identity to one of the C-terminal fragments of an IGFBP, preferably at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity.
- the IGFBP peptides comprise or consist or consist essentially of the TY1 domains, that is, comprise, consist or consist essentially of amino acids corresponding to amino acids 173-251 of SEQ ID No. 1 (IGFBP-1), amino acids 207-309 of SEQ ID No. 3 (IGFBP-2), amino acids 210-285 of SEQ ID No. 11 (IGFBP-3), amino acids 171-249 of SEQ ID No. 5 (IGFBP-4), amino acids 189-263 of SEQ ID No. 7 (IGFBP-5) or amino acids 160-234 of SEQ ID No. 9 (IGFBP-6).
- the IGFBP proteins and fragments thereof inhibit cathepsin activity, particularly cathepsin B activity, and thus are useful as active agents to delay or prevent acute or chronic disease states associated with cathepsin activity.
- disease states include, for example, neurodegenerative disorders including ischemic stroke (thrombotic or embolic in origin), hemmorhagic stroke and subsequent vascular phenomena, myocardial infarction, neurologic consequences of coronary bypass and grafting operations, head trauma, Alzheimer's Disease, age-associated dementia, vascular dementias, Parkinson's disease and amyotrophic lateral sclerosis.
- the IGFBP proteins and fragments thereof are particularly useful for inhibiting angiogenesis and/or tumorigenesis.
- the IGFBP proteins and fragments thereof are particularly useful in mammals, particularly in mammalian cells.
- proteases have the potential to cause significant tissue damage due to the hydrolysis of a wide variety of intracellular and extracellular substrates. Uncontrolled release of proteases can exacerbate the ongoing tissue damage initiated by primary mechanical injury. Lysosomal leakage or rupture with the subsequent release of proteases represents the greatest threat to neuronal survival. Abnormal increase in cathepsin B activity intra or extracellularly can affect protein degradation and cellular integrity. Cathepsin B has been recently associated with neuronal cell death and apoptosis. Upregulation of cathepsin B has been reported to occur in multiple neurodegenerative disorders including stroke, Alzheimer's disease, head trauma, dementia and the like.
- the active agents may be formulated as a medicament and can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are determined by the solubility and chemical properties of the active agent selected, the chosen route of administration, and standard pharmaceutical practice.
- a peptide comprising 20 or more consecutive amino acids of an amino acid sequence selected from the group consisting of: amino acids 1-259 of SEQ ID No. 1; amino acids 170-259 of SEQ ID No. 1; amino acids 173-251 of SEQ ID No. 1; amino acids 1-328 of SEQ ID No. 3; amino acids 107-328 of SEQ ID No. 3; amino acids 207-309 of SEQ ID No. 3; amino acids 1-272 of SEQ ID No. 7; amino acids 177-272 of SEQ ID No. 7; amino acids 189-263 of SEQ ID No. 7; amino acids 1-240 of SEQ ID No. 9; amino acids 151-240 of SEQ ID No. 9; amino acids 160-234 of SEQ ID No. 9; amino acids 1-291 of SEQ ID No. 11 and amino acids 210-285 of SEQ ID No. 11 in the preparation of a medicament for inhibiting angiogenesis.
- a peptide comprising at least 85% identity to amino acids 170-259 of SEQ ID No. 1 in the preparation of a medicament for inhibiting angiogenesis.
- a peptide comprising at least 85% identity to amino acids 107-328 of SEQ ID No. 3 in the preparation of a medicament for inhibiting angiogenesis.
- a peptide comprising at least 85% identity to amino acids 177-272 of SEQ ID No. 7 in the preparation of a medicament for inhibiting angiogenesis.
- a peptide comprising at least 85% identity to amino acids 151-240 of SEQ ID No. 9 in the preparation of a medicament for inhibiting angiogenesis.
- a peptide comprising 20 or more consecutive amino acids of an amino acid sequence selected from the group consisting of: amino acids 1-259 of SEQ ID No. 1; amino acids 170-259 of SEQ ID No. 1; amino acids 173-251 of SEQ ID No. 1; amino acids 1-328 of SEQ ID No. 3; amino acids 107-328 of SEQ ID No. 3; amino acids 207-309 of SEQ ID No. 3; amino acids 1-272 of SEQ ID No. 7; amino acids 177-272 of SEQ ID No. 7; amino acids 189-263 of SEQ ID No. 7; amino acids 1-240 of SEQ ID No. 9; amino acids 151-240 of SEQ ID No. 9; amino acids 160-234 of SEQ ID No. 9; amino acids 1-291 of SEQ ID No. 11 and amino acids 210-285 of SEQ ID No. 11 in the preparation of a medicament for inhibiting tumor growth.
- a peptide comprising at least 85% identity to amino acids 107-328 of SEQ ID No. 3 in the preparation of a medicament for inhibiting tumor growth.
- a peptide comprising at least 85% identity to amino acids 151-240 of SEQ ID No. 9 in the preparation of a medicament for inhibiting tumor growth.
- a peptide comprising 20 or more consecutive amino acids of an amino acid sequence selected from the group consisting of: amino acids 1-259 of SEQ ID No. 1; amino acids 170-259 of SEQ ID No. 1; amino acids 173-251 of SEQ ID No. 1; amino acids 1-328 of SEQ ID No. 3; amino acids 107-328 of SEQ ID No. 3; amino acids 207-309 of SEQ ID No. 3; amino acids 1-258 of SEQ ID No. 5; amino acids 157-258 of SEQ ID No. 5; amino acids 171-249 of SEQ ID No. 5; amino acids 1-272 of SEQ ID No. 7; amino acids 177-272 of SEQ ID No.
- a peptide comprising at least 85% identity to amino acids 170-259 of SEQ ID No. 1 in the preparation of a medicament for inhibiting cathepsin activity.
- a peptide comprising at least 85% identity to amino acids 151-240 of SEQ ID No. 9 in the preparation of a medicament for inhibiting cathepsin activity.
- a peptide comprising at least 85% identity to amino acids 1-291 of SEQ ID No. 11 in the preparation of a medicament for inhibiting cathepsin activity.
- a method of reducing angiogenesis by modulating the interaction of IGF with a receptor comprising regulating the concentration of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and/or IGFBP-6 in the vicinity of the receptor.
- the concentration of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-5 and/or IGFBP-6 is regulated.
- the angiogenic inhibiting peptide comprises 20 or more consecutive amino acids of any one of: amino acids 1-259 of SEQ ID No. 1 (full length IGFBP-1); amino acids 170-259 of SEQ ID No. 1 (SEQ ID No. 2, C-terminal fragment of IGFBP-1); amino acids 1-328 of SEQ ID No. 3 (full length IGF2); amino acids 107-328 of SEQ ID No. 3 (C-terminal fragment of IGF2, SEQ ID No. 4); amino acids 1-258 of SEQ ID No. 5 (full length IGF4); amino acids 157-258 of SEQ ID No. 5 (C-terminal fragment of IGF4, SEQ ID No. 6); amino acids 1-272 of SEQ ID No.
- amino acid locations within IGFBPs likely to tolerate substitution are not likely to be highly conserved between IGFBP family members.
- tolerated conserved substitutions may be determined by comparing the sequences as well. It is of note that as discussed above, the percent of homology of the IGFBP1-6 sequences varies between 54-70%.
- the IGFBP peptide sequence may be flanked on either side or both by additional amino acids which may or may not be 'native' IGFBP sequence or may be within a carrier or presenting peptide as known in the art.
- C-terminal fragments discussed above represent fragments of native sequence shown to have significant activity. Accordingly, longer fragments, including additional native or in some embodiments non-native amino acids are within the scope of the invention.
- nucleic acid sequences encoding one or more of the amino acid sequences described above.
- sequence identity is preferably at least 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100%. In some cases the sequence includes non-natural and/or chemically modified amino acids.
- a method of inhibiting angiogenic transformation of endothelial cells comprising administering IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 or IGFBP-6 or a fragment or variant thereof as described above.
- IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 or IGFBP-6 or a fragment or variant thereof as described above there are many methods known in the art for measurement of angiogenesis.
- inhibition of angiogenesis may be based on a comparison between a treatment group which is administered an effective amount of the IGFBP protein fragment as described herein and an untreated or mock-treated control. It is of note that the control would not necessarily need to be repeated each time.
- the IGFBP peptide as discussed herein may be combined with a matrix, gel or other similar compound such that the IGFBP peptide is substantially retained in a localized area following application thereof to the site of interest.
- a peptide comprising or consisting of or consisting essentially of amino acids 1-259 of SEQ ID No. 1 (full length IGFBP-1); amino acids 170-259 of SEQ ID No. 1 (SEQ ID No. 2, C-terminal fragment of IGFBP-1); amino acids 1-328 of SEQ ID No. 3 (full length IGFBP-2); amino acids 107-328 of SEQ ID No. 3 (C-terminal fragment of IGFBP-2, SEQ ID No. 4); amino acids 1-258 of SEQ ID No. 5 (full length IGFBP-4); amino acids 157-258 of SEQ ID No. 5 (C-terminal fragment of IGFBP-4, SEQ ID No.
- amino acid sequences of the invention will include non-natural amino acids and/or modified amino acids. Modifications of interest include cyclization, derivitivization and/or glycosylation of one or more functional groups, as discussed above.
- expression vectors e.g. bacterial, viral, mammalian, yeast, etc
- expression vectors e.g. bacterial, viral, mammalian, yeast, etc
- amino acids 1-258 of SEQ ID No. 5 full length IGFBP-4
- amino acids 157-258 of SEQ ID No. 5 C-terminal fragment of IGFBP-4, SEQ ID No. 6
- amino acids 1-272 of SEQ ID No. 7 full length IGFBP-5
- amino acids 177-272 C-terminal fragment of IGFBP-5, SEQ ID No. 8
- amino acids 1-240 of SEQ ID No. 9 full length IGFBP-6
- amino acids 151-240 of SEQ ID No. 9 C-terminal fragment of IGFBP-6, SEQ ID No. 10
- amino acids 1-291 of SEQ ID No. 11 may be operably linked to a suitable promoter for expression in the desired host cell.
- the IGFBP peptides comprise or consist or consist essentially of the TY1 domains, that is, comprise, consist or consist essentially of amino acids corresponding to amino acids 173-251 of SEQ ID No. 1 (IGFBP-1), amino acids 207-309 of SEQ ID No. 3 (IGFBP-2), amino acids 210-285 of SEQ ID No. 11 (IGFBP-3), amino acids 171-249 of SEQ ID No. 5 (IGFBP-4), amino acids 189-263 of SEQ ID No. 7 (IGFBP-5) or amino acids 160-234 of SEQ ID No. 9 (IGFBP-6).
- viral vectors e.g. retrovirus, adenovirus, adeno-associated virus, herpes-simplex
- non-viral methods of DNA transfer e.g. naked DNA, liposomes and molecular conjugates, nanoparticles
- Angiogenesis the formation of new capillary blood vessels, plays a crucial role in many physiological and pathological settings, including embryonic development, wound healing, ocular diseases, and tumor growth and metastasis.
- new capillaries are formed by a process of sprouting from existing microvessels: in response to locally released angiogenic factors, microvascular endothelial cells degrade their basement membrane and subsequently invade the surrounding interstitial matrix, in which they form tubular capillary sprouts.
- Cancer cells are cells that have lost the ability to divide in a controlled fashion.
- a tumor consists of a population of rapidly dividing and growing cancer cells. Mutations rapidly accrue within the population. These mutations allow the cancer cells to develop drug resistance and escape therapy. Tumors cannot grow beyond a certain size, generally 1-2 mm 3 , without blood supply due to a lack of oxygen and other essential nutrients. Tumors induce blood vessel growth (angiogenesis) by secreting various growth factors. Growth factors, such as bFGF, IGF-1 and VEGF can induce capillary growth into the tumor, allowing for tumor expansion. Endothelial cells have long been considered genetically more stable than cancer cells. This genomic stability confers an advantage to targeting endothelial cells using antiangiogenic therapy, compared to chemotherapy directed at cancer cells, which rapidly mutate and acquire 'drug resistance' to treatment.
- the human glioma cell line U87MG was established from surgically removed type III glioma/glioblastoma and obtained from ATCC.
- Cells (5x10 4 cells/ml) were plated in poly-L-lysine pre-coated dishes and grown at 37°C in D-MEM (DME) supplemented with 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 10% heat-inactivated fetal bovine serum (FBS) (HyClone, Logan, Utah) in humidified atmosphere of 5% CO 2 /95% air until reached 80% confluence. Then, media were removed and the cells incubated for 3 days in serum-free DME to obtain conditioned media (CM). Conditioned media were collected and filtered (Millex-GV sterilizing filter membrane, 0.22 ⁇ m). Cells were then harvested for molecular and biochemical assays.
- DME D-MEM
- FBS heat-inactivated fetal bovine serum
- HBEC Human brain endothelial cells
- HBEC HBEC were separated from smooth muscle cells with cloning rings and grown at 37°C in HBEC media containing Earle's salts, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 4.35 g/L sodium bicarbonate, and 3 mM L-glutamine, 10% FBS, 5% human serum, 20% of media conditioned by murine melanoma cells (mouse melanoma, Cloudman S91, clone M-3, melanin-producing cells), 5 ⁇ g/ml insulin, 5 ⁇ g/ml transferrin, 5 ng/ml selenium, and 10 ⁇ g/ml endothelial cell growth supplement.
- EPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
- HBEC cultures were routinely characterized morphologically and biochemically. More than 95% of cells in culture stained immunopositive for the selective endothelial markers, angiotensin II-converting enzyme and Factor VIII-related antigen, incorporated fluorescently labelled Ac-LDL, and exhibited high activities of the blood-brain barrier- specific enzymes, ⁇ -glutamyltranspeptidase and alkaline phosphatase.
- IGFBP-1 Insulin-like growth factor-binding protein 1 precursor (IGFBP-1) (IBP-1/IBP1) (Gene accession number NM 000596.2 )
- IGFBP-1 gene was amplified by PCR using forward (CTAGAATTCCACCATGTCAGAGGTCCCCGTTG, SEQ ID No. 12) and reverse (CTAACCGGTGTTTTGTACATTAAAATATATC, SEQ ID No. 13) oligos, digested by EcoRI and AgeI, and cloned in pTT5SH8Q2 vector.
- the resulting protein contains a C-terminal octahistidine tag separated from the core protein by a TG linker (see below).
- Normal font IGFBP-1 amino acid sequence Italics: linker+(His) 8 GGQ tag
- IGFBP-1 C-terminal domain (CIBP1, Gene accession number AAH57806.1 )
- CIBP1 gene was codon-optimized and synthesized by GeneScript Corporation digested by NheI and cloned in NheI-linearized pTT28 vector.
- the resulting synthetic gene contains a modified SEAP signal peptide and an octahistidine tag separated from the core protein by an ASSGSSTG linker (see below).
- ASSGSSTG linker see below.
- Normal font IGFBP1 C-terminal amino acid sequence (should include IAS residues)
- IGFBP-2 Insulin-like growth factor-binding protein 2 precursor (IGFBP-2) (IBP-1/IBP2) (Gene accession number NM_000597)
- CIBP2 was amplified with forward (CTAGCTAGCAAGGGTGGCAAGCATCAC, SEQ ID No. 16) and reverse (TAGGGATCCCTGCATCCGCTGGGTGTGC, SEQ ID No. 17) primers, digested with NheI and BamHI and cloned in-frame pYD1 vector.
- the resulting protein contains the SEAP signal peptide and a C-terminal StreptagII-octahistidine fusion tag separated from the core protein by a DP linker (see below).
- IGFBP-4 Insulin-like growth factor binding protein 4 precursor (IGFBP-4) (IBP-4/IBP4) (Gene accession number NP_001543.2)
- IGFBP4 was amplified with forward (TAAGAATTCGCCACCATGCTGCCCCTCTGCCT, SEQ ID No. 18) and reverse (TTAGGATCCACCTCTCGAAAGCTGTCAGCC, SEQ ID No. 19) primers, digested with NheI and BamHI and cloned in pTT5SH8Q1 vector.
- the resulting protein contains a C-terminal StreptagII-octahistidine fusion tag separated from the core protein by a DP linker (see below).
- Normal font IGFBP4 amino acid sequence
- Italics Streptag-II / (His) 8 G tag (SH8Q1)
- IGFBP-4 C-terminal (CIBP4, gene Accession number NP_001543.2)
- CIBP4 was amplified with forward (GCCGCTAGCAAGGTCAATGGGGCGCCCCGGGA, SEQ ID No. 20) and reverse (TTAGGATCCACCTCTCGAAAGCTGTCAGCC, SEQ ID No. 21) primers, digested with NheI and BamHI and cloned in pYD1 vector.
- the resulting protein contains the SEAP signal peptide and a C-terminal StreptagII-octahistidine fusion tag separated from the core protein by a DP linker (see below).
- IGFBP-5 C-terminal domain (CIBP5, Accession number NP_000590.1 )
- IGFBP-6 Insulin-like growth factor binding protein 6 precursor (IGFBP-6) C-terminal (CIBP6, Accession number NM_002178.2)
- IGFBP construct were produced following large-scale transfection of HEK293-EBNA1 (293E) cells.
- Transfection of suspension-growing 293E (clone 6E) cells was done in shaker flasks. Cells were grown in F17 medium (Invitrogen) and transfected at 1x10 6 cells/ml using 25 kDa linear polyethylenimine as previously described (Durocher et al 2002) with some modifications.
- F17 medium Invitrogen
- 750 ug of plasmid DNA was mixed with 1500 ug of PEI and the mixture was incubated for 15 minutes before its addition to the culture.
- Medium was harvested 5 days later, clarified by filtration through a 0.45 um filter, and loaded on Fractogel cobalt column.
- CLT Capillary-like tube
- HBEC (40,000 cells) were suspended in 500 ⁇ l of either DME, serum-free U87MG CM (collected as described in Cell Cultures) or growth factors (VEGF, IGF-1, bFGF) in the absence or presence of 20 nM of either full length recombinant IGFBP-1 (IBP1, produced at BRI-NRC), IGFBP-2 (IBP2, produced at BRI-NRC and purchased from R&D systems, Minneapolis), IGFBP-3 (IBP3, from R&D systems), IGFBP-4 (IBP4, produced at BRI-NRC), IGFBP-5 (IBP5, produced at BRI-NRC and purchased from R&D systems) and IGFBP-6 (IBP6, from R&D systems) or the C-terminal protein fragments of IGFP-1 (CIBP1), IGFBP-2 (CIBP2), IGFBP-4 (CIBP4), IGFBP-5 (CIBP5) and IGFBP-6 (CIBP6), all produced at BRI-NRC).
- IBP1 IGFBP
- U87MG cell growth in semi-solid agar was determined in the absence or presence of 20 nM of either CIBP-4, CIBP-5 or dybutyril cAMP (dB-cAMP) as described previously (Moreno et al., 2006).
- dB-cAMP dybutyril cAMP
- Approximately 15,000 cells ⁇ treatment were resuspended in 150 ⁇ l medium containing 0.3% agar, and seeded onto a well of a 24-well plate previously layered with 250 ⁇ l 0.6% agar.
- the solidified cell layer was covered with 50 ⁇ l DME ⁇ treatment which was replaced every three days over a 21 day period.
- Phase contrast images (6 fields/well) were captured using a digital video camera (Olympus U-CMT) and analyzed with Northern Eclipse v.5.0 software. Color images were transformed to grey scale, thresholded, and then converted to binary images. Number and area of colonies per field were calculated. In order to measure cell viability, at the end of the experiment, 40 ⁇ l alamar blue was added to each well and fluorescence readings were performed every 10 min for a period of 180 min. Experiments were repeated 2-3 times in triplicates.
- U87MG cells were plated at a density of 10 4 cells/well in 500 ⁇ l of U87MG media on poly-L-lysine-coated 24-well plates. Three days later, U87MG media was removed, cells rinsed twice with HBSS and incubated for 2 h or 18 h in 300 ⁇ l of either DME or DME supplemented with either 20 nM of the full length proteins IBP1, IBP2, IBP3, IBP4, IBP5, IBP6 or 20 nM the C-terminal CIBP1, CIBP2, CIBP4, CIBP5, CIBP6.
- Fertilized chicken (Gallus gallus) eggs were obtained from the Canadian Food Inspection Agency and placed into an egg incubator at 37°C and 67-70% humidity (day 0). At day 3, windows were cut in the egg shell and covered with surgical tape (Durapore, ) until day 10. Then, a sterile Nunc Thermanox (Nunc Inc., Naperville., IL) plastic ring was placed onto the CAM, the delimited surface gently lacerated with a scalpel blade and a pellet of 10 6 U87MG cells deposited into the center of the ring. At days 11-14, thirty ⁇ l of either sterile water + 6% DMSO alone (vehicle) or in combination of 250 nM of CIBP-4 was applied to the tumors. Digital photos were taken using a Canon 40D camera. At day 17, tumors were carefully removed from the CAM and weighted.
- Confocal microscopy indicates that the C-terminal (CIBP-4, nt 155-258) protein fragment of IGFBP-4 conjugated to alexa fluor 647 (CIBP-4-AF147) internalizes into human brain endothelial cells (HBEC).
- the proteins show punctuate perinuclear localization in vesicle-like structures ( Fig. 1 ). This indicates that CIBP-4 most likely recognizes and binds specific proteins contained in these vesicles.
- LysotrackerTM a permeable acidotropic probe for selective fluorescent labeling of lysosomes
- CIBP-4 can inhibit angiogenic response induced by U87MG conditioned media and by different growth factors, including bFGF, VEGF and IGF-1.
- bFGF vascular endothelial growth factor
- VEGF vascular endothelial growth factor
- IGF-1 vascular endothelial growth factor-1
- IGFBP-2 and IGFBP-5 from R&D systems were used as positive controls, to compare their efficacy to that of the corresponding BRI-NRC produced proteins.
- all the IGFBP members and their corresponding C-terminal fragment were potent inhibitors of both angiogenesis (CLT formation by HBEC in Matrigel) and cathepsin B activity, with the exception of IGFBP-2 that did not inhibit the angiogenic response and intracellular cathepsin B activity induced in HBEC by either U87MG CM or bFGF.
- IGFBP-2 was able to completely inhibit the angiogenic response and intracellular cathepsin B activity induced by VEGF and IGF-1.
- confocal microscopy was performed to map intracellular cathepsin B activity in U87MG cells. As shown in Fig. 6 , high levels of cathepsin B activity were observed in U87MG cells predominantly in the cytoplasm and the plasma membrane along side the cellular processes.
- IGFBP-4 and the C-terminal IGFBP-4 fragment were able to reduce U87MG colony formation in soft agar.
- CIBP1 CIBP6 ( ⁇ 25%)
- CIBP2 CIBP4 ( ⁇ 50%)
- ⁇ dB-cAMP positive control, ⁇ 65%
- CA074-ME ⁇ 70%).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83793006P | 2006-08-16 | 2006-08-16 | |
EP07800446.2A EP2056868B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07800446.2A Division EP2056868B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
EP07800446.2 Division | 2007-08-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2462946A1 true EP2462946A1 (fr) | 2012-06-13 |
EP2462946B1 EP2462946B1 (fr) | 2014-07-09 |
Family
ID=39081875
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07800446.2A Not-in-force EP2056868B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
EP12157648.2A Not-in-force EP2462946B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'activité de la cathepsine |
EP12157644.1A Not-in-force EP2462945B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07800446.2A Not-in-force EP2056868B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12157644.1A Not-in-force EP2462945B1 (fr) | 2006-08-16 | 2007-08-16 | Procédé d'inhibition de l'angiogenèse, de la tumorigenèse et de l'activité de la cathepsine à l'aide d'une protéine de liaison au facteur de croissance de type insuline |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100279937A1 (fr) |
EP (3) | EP2056868B1 (fr) |
CA (1) | CA2659585A1 (fr) |
ES (1) | ES2418434T3 (fr) |
WO (1) | WO2008019491A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2437768B1 (fr) * | 2009-06-04 | 2016-08-10 | The University of North Carolina At Chapel Hill | Composés et procédés pour traiter des troubles osseux et réguler le poids |
RU2019125634A (ru) | 2017-02-06 | 2021-03-09 | Элайз Фарма Сас | Соединения, композиции и их применения для улучшения костных расстройств |
CA3100665A1 (fr) | 2018-05-24 | 2019-11-28 | Amolyt Pharma | Domaine de liaison a l'heparine d'igfbp-2 dans le traitement de troubles metaboliques |
EP3884948A1 (fr) * | 2020-03-26 | 2021-09-29 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibiteurs de cathepsine et leurs utilisations |
WO2021194491A1 (fr) * | 2020-03-26 | 2021-09-30 | Desmond Mascarenhas | Peptides immunomodulateurs modifiés de manière covalente avec des petites molécules |
CA3207815A1 (fr) * | 2021-03-09 | 2022-09-15 | Desmond Mascarenhas | Modulation de lignee cellulaire chez les mammiferes par des immodulines synthetiques |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080379A2 (fr) * | 2003-03-03 | 2004-09-23 | Lmd | Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2160154A1 (fr) * | 1993-04-07 | 1994-10-13 | George N. Cox | Methodes d'utilisation de proteines de fixation de facteur de croissance de type insuline |
US6395890B1 (en) * | 1998-02-20 | 2002-05-28 | Zymogenetics, Inc. | Nucleic acids encoding connective tissue growth factor homologs |
AU6515499A (en) * | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
WO2000069454A1 (fr) * | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression de l'igfbp-2 endogene visant a inhiber le cancer |
US6727066B2 (en) * | 2000-07-28 | 2004-04-27 | Incyte Corporation | Genes expressed in treated human C3A liver cell cultures |
US7198895B2 (en) * | 2000-11-14 | 2007-04-03 | Mohanlal Ramon W | In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals |
WO2002090580A1 (fr) * | 2001-05-03 | 2002-11-14 | National Cancer Centre Of Singapore Pte Ltd | Identification du cancer du foie par detection de l'expression aberrante de proteines se liant au facteur de croissance analogue a l'insuline |
US6709036B1 (en) * | 2002-11-14 | 2004-03-23 | Shape Corporation | Bumper with hitch |
AU2002950188A0 (en) * | 2002-07-12 | 2002-09-12 | The University Of Adelaide | Altered insulin-like growth factor binding proteins |
US7191068B2 (en) * | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
DE10316701A1 (de) * | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
WO2005049648A2 (fr) * | 2003-07-09 | 2005-06-02 | The University Of Iowa Research Foundation | Proteines de liaison utilisees en chimiotherapie |
WO2006017824A2 (fr) | 2004-08-06 | 2006-02-16 | The Trustees Of Columbia University In The City Of New York | Procedes relatifs a igf-bp3 permettant d'inhiber la croissance de tumeur |
US7077441B2 (en) * | 2004-08-09 | 2006-07-18 | Hwa Sun Lee | Bumper reinforcement for an automobile |
US20100028302A1 (en) * | 2004-09-27 | 2010-02-04 | Ludwig-Maximilians- Universität München | Use of IGFBP-2 in Senescence Diseases and for the Maintenance of Organ Functions |
WO2006086891A1 (fr) * | 2005-02-18 | 2006-08-24 | National Research Council Of Canada | Composes de proteine 4 de liaison du facteur de croissance de type insuline et methodes permettant d'inhiber l'angiogenese et la croissance tumorale dans des cellules de mammiferes |
WO2007022635A2 (fr) * | 2005-08-25 | 2007-03-01 | The University Of Manitoba | Methodes permettant de reduire la croissance d'une tumeur de la prostate, dans lesquelles est utilisee la proteine-3 se liant au facteur de croissance analogue a l'insuline (igfbp-3) |
-
2007
- 2007-08-16 EP EP07800446.2A patent/EP2056868B1/fr not_active Not-in-force
- 2007-08-16 EP EP12157648.2A patent/EP2462946B1/fr not_active Not-in-force
- 2007-08-16 ES ES07800446T patent/ES2418434T3/es active Active
- 2007-08-16 WO PCT/CA2007/001418 patent/WO2008019491A1/fr active Application Filing
- 2007-08-16 EP EP12157644.1A patent/EP2462945B1/fr not_active Not-in-force
- 2007-08-16 US US12/377,537 patent/US20100279937A1/en not_active Abandoned
- 2007-08-16 CA CA002659585A patent/CA2659585A1/fr not_active Abandoned
-
2015
- 2015-09-28 US US14/867,078 patent/US20160082083A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080379A2 (fr) * | 2003-03-03 | 2004-09-23 | Lmd | Extrait de pangium edule et lignanes utilisables comme inhibiteur de cathepsines ou ayant une action anti-necrotique |
Non-Patent Citations (1)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
Also Published As
Publication number | Publication date |
---|---|
EP2056868B1 (fr) | 2013-04-17 |
WO2008019491A1 (fr) | 2008-02-21 |
EP2462945A2 (fr) | 2012-06-13 |
EP2056868A4 (fr) | 2009-11-25 |
EP2462945B1 (fr) | 2014-06-04 |
EP2462945A3 (fr) | 2012-09-05 |
WO2008019491A8 (fr) | 2014-03-20 |
US20160082083A1 (en) | 2016-03-24 |
ES2418434T3 (es) | 2013-08-13 |
EP2462946B1 (fr) | 2014-07-09 |
US20100279937A1 (en) | 2010-11-04 |
EP2056868A1 (fr) | 2009-05-13 |
CA2659585A1 (fr) | 2008-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160082083A1 (en) | Method of inhibiting angiogenesis, tumorigenesis and cathepsin activity | |
JP7041187B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
JP7007423B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
KR102201430B1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
AU784338B2 (en) | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same | |
US20080241835A1 (en) | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same | |
Lim et al. | The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin | |
US10316061B2 (en) | Synthesis of cell penetrating peptides for drug delivery and stem cell applications | |
JP2005504801A (ja) | Igf結合タンパク質由来のペプチドまたは低分子 | |
WO2006041205A1 (fr) | Promoteur d'angiogenese | |
Yamada et al. | Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53 | |
US7507712B2 (en) | NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer | |
JP2010239971A (ja) | 細胞におけるペルオキシソームカタラーゼ機能の促進 | |
US20090048158A1 (en) | Insulin-Like Growth Factor Binding Protein-4 Compounds and Methods for Inhibiting Angiogenesis and Tumor Growth in Mammalian Cells | |
JP2006501812A (ja) | Ku−70由来のbax抑制ペプチド類および損傷細胞を保護するためのその使用 | |
JP2006515168A5 (fr) | ||
Chang | Fibronectin-rhamm interactions, which are required for cell motility, regulate podosome formation | |
EP1287161A2 (fr) | Genes exprimes de maniere differentielle impliques dans l'angiogenese, polypeptides codes par lesdits genes, et techniques d'utilisation de ces genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2056868 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
17P | Request for examination filed |
Effective date: 20121213 |
|
17Q | First examination report despatched |
Effective date: 20130116 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140124 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MORENO, MARIA J. |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2056868 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 676327 Country of ref document: AT Kind code of ref document: T Effective date: 20140715 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007037612 Country of ref document: DE Effective date: 20140821 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 676327 Country of ref document: AT Kind code of ref document: T Effective date: 20140709 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140709 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141010 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141009 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141110 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141109 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007037612 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140831 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20150430 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007037612 Country of ref document: DE Effective date: 20150303 |
|
26N | No opposition filed |
Effective date: 20150410 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20141009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141009 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150303 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140816 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140909 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140816 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20070816 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140709 |